Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT)
Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Legorreta Cancer Center at Brown University, shared an article by John W K Chia, et al. on LinkedIn:
“Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trial.”
, Professor of Medicine Emeritus at Brown University, reshared the post, adding:
“Disappointing information. But why such a high dose of ASA? That’s out of line with recent studies.
Those who regularly took aspirin had a colorectal cancer 10-year cumulative incidence of 1.98 percent, compared with 2.95 percent among those who did not take aspirin.
“Based on prior studies, the best evidence supports daily low-dose (81 mg) aspirin for prevention.”
Maybe another study using lower doses eg. 81mg daily vs 81mg three times a week might be worthwhile considering.
These doses are more also more effective at preventing cardiovascular issues than higher doses.”
Authors: John W K Chia, et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023